摘要
Abstract
Objective Toobservetheeffectsoftrimetazidineonendothelialfunctioninpatientswithchronicheartfail-ure,inordertoprovideatheoreticalbasisfortreatment.Methods Sixty-eightpatientswithchronicheartfailurefromJuly 2012 to July 2013 were randomly divided into two groups(34 per group). The control group received conventional medicine such as diuretics,beta blockers,angiotensin -converting enzyme inhibitors( ACEI),and digitalis for treatment of heart failure. The trimetazidine group received trimetazidine as a control. Both groups were treated for four weeks. Flow-mediated vasodila-tion of the brachial artery(FmD),serum nitric oxide(NO),and endothelin-1(ET-1)in the two groups were measured beforeandaftertreatment.Results TherewasnostatisticallysignificantofD0,D1,FmDfunctionbetweencontrolgroupand trimetazidine group before treatment(P﹥0. 05). There was statistically significant of D1,FmD function between control group and trimetazidine group after treatment(P﹤0. 05). The FmD of the trimetazidine group was significantly superior to the control group(P﹤0. 05). Serum NO in the trimetazidine group was significantly increased,and serum ET -1 in the trimetazidine group was significantly decreased than control group after treatment(P﹤0. 05). After treatment,serum NO levels higher than before treatment,and pre-treatment serum ET-1 levels below(P﹤0. 05). Blood pressure,heart rate,hepatic and renal function,and routine analysis of blood,urine,and stool between groups were compared before and after treatment,and showed nostatisticallysignificantdifference(P﹥0.05).Conclusion Trimetazidine,comparedwithconventionaltherapy,cansignif-icantly improve vascular endothelial function of patients with chronic heart failure by increasing the serum nitric oxide and reducing endothelin-1 levels. There were no demonstrable side effects.关键词
曲美他嗪/慢性心力衰竭/血管内皮功能/不良反应Key words
Trimetazidine/Chronicheartfailure/Endothelialfunction/Adversereactions分类
医药卫生
